Default Category
-
BCE Inc.: In Play
Stephen R. Foerster; Heather TobinCase IVEY-9B09N018-EFinance, StrategyBCE Inc. (BCE), one of Canada's leading telecommunications companies, had struggled under its weak stock price performance and low valuation relative to its comparable peers, and faced increasing pressure from its largest shareholder, the powerful Ontario Teachers' Pension Plan (Teachers'). On March 29, 2007, it was reported that private equity firm Kohlberg Kravis & Roberts (KKR) had held informal meetings with BCE executives in the hopes of lau...Starting at €8.20
-
BCE Inc.: Facing the Future
Stephen R. Foerster; W. Glenn Rowe; Heather TobinCase IVEY-9B09N015-EFinance, StrategyBCE Inc. (BCE), one of Canada's leading integrated communications companies, faced numerous challenges. In the key wireless communications market, BCE was trailing its competitors on growth and revenue. BCE's share price was underperforming and shareholders, including the powerful Ontario Teachers' Pension Plan, were becoming concerned. In addition there were regulatory changes on the horizon that could have a serious impact on BCE's wireless div...Starting at €8.20
-
The Heat is ON
Mark Zbaracki; Maziar RazCase IVEY-9B14M097-EEntrepreneurship, StrategyIn January 2014, the chief executive officer of AutoTherm, a small smart-thermostat design company located in Toronto, Canada, was considering the company’s future in light of the uncertainties and fast changing dynamics of the industry. As an incumbent and small engineering firm, AutoTherm’s plans to sell its first product, B133, through partnership with a large electronics company had not been quite successful. Given the dire state of the compa...Starting at €8.20
-
Hoffmann-La Roche: Pricing the Zelboraf Melanoma Treatment for Canada
Mark Zbaracki; Jedy WangCase IVEY-9B16M138-EStrategyThe Canadian brand manager of Zelboraf had to decide how to introduce and price Zelboraf in the Canadian market. Zelboraf was a breakthrough discovery in treatment for melanoma cancer patients. Hoffmann-La Roche (Roche) began developing Zelboraf in 2005. During the clinical trials, the drug yielded such positive results in targeting late-stage (metastatic) melanoma cancer that Roche ended clinical trials early in order to expedite FDA approval an...Starting at €8.20